157 related articles for article (PubMed ID: 29782561)
1. Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.
Facchinetti F; Friboulet L
Transl Lung Cancer Res; 2018 Apr; 7(Suppl 2):S103-S106. PubMed ID: 29782561
[No Abstract] [Full Text] [Related]
2. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
3. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N; Gillis R; Kilickap S; Froesch P; Orlov S; Filippova E; Demirci U; Christopoulos P; Cicin I; Basal FB; Yilmaz C; Fedor M; Korkmaz T; Paydas S; Gautschi O; Zirtiloglu A; Eralp Y; Cinkir HY; Sezer A; Erman M; Tural D; Turna H; Mazieres J; Dudnik E; Reguart N; Camidge DR; Ng TL; Şenler FÇ; Beypınar İ; Yazılıtaş D; Demirkazık A; Karaoğlu A; Okutur K; Coşkun HŞ; Şendur MAN; Isikdogan A; Cabuk D; Yumuk PF; Yıldız I; Kaplan MA; Özyılkan Ö; Öztop İ; Olmez OF; Aydin K; Aydıner A; Meydan N; Grinberg RD; Roisman LC
Lung Cancer; 2020 Oct; 148():48-54. PubMed ID: 32799090
[TBL] [Abstract][Full Text] [Related]
4. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Zhu VW; Lin YT; Kim DW; Loong HH; Nagasaka M; To H; Ang YL; Ock CY; Tchekmedyian N; Ou SI; Syn NL; Reungwetwattana T; Lin CC; Soo RA
J Thorac Oncol; 2020 Sep; 15(9):1484-1496. PubMed ID: 32360579
[TBL] [Abstract][Full Text] [Related]
5. Later-Line Treatment with Lorlatinib in
Hochmair MJ; Fabikan H; Illini O; Weinlinger C; Setinek U; Krenbek D; Prosch H; Rauter M; Schumacher M; Wöll E; Wass R; Brehm E; Absenger G; Bundalo T; Errhalt P; Urban M; Valipour A
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33171712
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
7. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced
Thummalapalli R; Choudhury NJ; Ehrich F; Beardslee T; Brazel D; Zhang SS; Merchant S; Chen MF; Heller G; Ramalingam SS; Ou SI; Mileham KF; Riely GJ
JTO Clin Res Rep; 2023 Aug; 4(8):100546. PubMed ID: 37644967
[TBL] [Abstract][Full Text] [Related]
8. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
9. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
11. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
[TBL] [Abstract][Full Text] [Related]
12. Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Facchinetti F; Levy A; Ammari S; Naltet C; Lavaud P; Aldea M; Vasseur D; Planchard D; Besse B
Cancer Manag Res; 2021; 13():2805-2810. PubMed ID: 33814929
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
14. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Yang J; Gong W
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T; Hayashi H; Satouchi M; Goto Y; Niho S; Nogami N; Hida T; Takahashi T; Sakakibara-Konishi J; Morise M; Nagasawa T; Suzuki M; Ohkura M; Fukuhara K; Thurm H; Peltz G; Nishio M
Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Soo RA; Huat Tan E; Hayashi H; Seto T; Lin CC; Ou SI; Kim DW; Liu G; Abbattista A; Martini JF; Hooi Wong C; Toffalorio F; Solomon BJ
Lung Cancer; 2022 Jul; 169():67-76. PubMed ID: 35660971
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
18. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
19. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
20. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N; Christopoulos P; Kauffmann-Guerrero D; Stratmann J; Riedel R; Schaefer M; Alt J; Gütz S; Christoph DC; Laack E; Faehling M; Fischer R; Fenchel K; Haen S; Heukamp L; Schulz C; Griesinger F
Ther Adv Med Oncol; 2021; 13():1758835920980558. PubMed ID: 33613692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]